Zhanna Gaulen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2462080/publications.pdf

Version: 2024-02-01

1684188 1720034 9 50 5 7 citations h-index g-index papers 9 9 9 72 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. European Addiction Research, 2022, 28, 56-67.	2.4	3
2	Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up. Journal of Substance Abuse Treatment, 2022, 135, 108656.	2.8	1
3	Risk of Relapse Among Opioidâ€Dependent Patients Treated With Extendedâ€Release Naltrexone or Buprenorphineâ€Naloxone: A Randomized Clinical Trial. American Journal on Addictions, 2021, 30, 453-460.	1.4	2
4	Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. European Addiction Research, 2019, 25, 303-309.	2.4	7
5	Beyond medication: Life situation of older patients in opioid maintenance treatment. Addiction Research and Theory, 2019, 27, 305-313.	1.9	6
6	Health and social issues among older patients in opioid maintenance treatment in Norway. NAD Nordic Studies on Alcohol and Drugs, 2017, 34, 80-90.	1.3	7
7	Interest in Extended Release Naltrexone among Opioid Users. European Addiction Research, 2016, 22, 301-305.	2.4	5
8	An Overview of Youth Substance Abuse Recovery Strategies in Norway. Journal of Groups in Addiction and Recovery, 2016, 11, 228-239.	0.4	1
9	Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). BMC Pharmacology & mp; Toxicology, 2016, 17, 18.	2.4	18